Equities research analysts predict that Aetna Inc. (NYSE:AET) will announce sales of $15.30 billion for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Aetna’s earnings. The lowest sales estimate is $14.75 billion and the highest is $15.67 billion. Aetna posted sales of $15.90 billion during the same quarter last year, which suggests a negative year-over-year growth rate of 3.8%. The company is scheduled to report its next quarterly earnings report before the market opens on Thursday, August 3rd.

On average, analysts expect that Aetna will report full-year sales of $15.30 billion for the current fiscal year, with estimates ranging from $59.54 billion to $61.58 billion. For the next financial year, analysts forecast that the business will post sales of $63.92 billion per share, with estimates ranging from $61.54 billion to $67.20 billion. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Aetna.

Aetna (NYSE:AET) last issued its quarterly earnings results on Tuesday, May 2nd. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.36 by $0.35. The company had revenue of $15.17 billion during the quarter, compared to analysts’ expectations of $15.39 billion. Aetna had a net margin of 1.84% and a return on equity of 17.75%. The business’s quarterly revenue was down 3.4% on a year-over-year basis. During the same period last year, the business earned $2.30 EPS.

A number of equities analysts have recently weighed in on the company. Jefferies Group LLC reaffirmed a “hold” rating and set a $133.00 target price on shares of Aetna in a research report on Thursday, April 13th. Zacks Investment Research lowered Aetna from a “buy” rating to a “hold” rating in a research report on Wednesday, April 5th. Deutsche Bank AG assumed coverage on Aetna in a research report on Wednesday, April 5th. They set a “hold” rating and a $135.00 target price on the stock. Cleveland Research raised Aetna from a “neutral” rating to a “buy” rating in a research report on Thursday, May 11th. Finally, Barclays PLC reaffirmed an “overweight” rating and set a $162.00 target price on shares of Aetna in a research report on Monday, May 15th. Seven investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $152.46.

COPYRIGHT VIOLATION WARNING: This piece was reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/07/15/aetna-inc-aet-expected-to-announce-quarterly-sales-of-15-30-billion.html.

In other Aetna news, EVP Margaret M. Mccarthy sold 27,028 shares of the company’s stock in a transaction on Wednesday, June 7th. The stock was sold at an average price of $149.23, for a total value of $4,033,388.44. Following the completion of the transaction, the executive vice president now owns 33,563 shares in the company, valued at approximately $5,008,606.49. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Mark T. Bertolini sold 103,547 shares of the company’s stock in a transaction on Wednesday, May 17th. The shares were sold at an average price of $140.79, for a total value of $14,578,382.13. Following the completion of the transaction, the chairman now owns 659,888 shares of the company’s stock, valued at approximately $92,905,631.52. The disclosure for this sale can be found here. 0.90% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in AET. Liberty Capital Management Inc. increased its position in shares of Aetna by 206.9% in the second quarter. Liberty Capital Management Inc. now owns 933 shares of the company’s stock worth $144,000 after buying an additional 629 shares during the period. FTB Advisors Inc. increased its position in shares of Aetna by 11.0% in the first quarter. FTB Advisors Inc. now owns 977 shares of the company’s stock worth $125,000 after buying an additional 97 shares during the period. Signature Estate & Investment Advisors LLC acquired a new position in shares of Aetna during the first quarter worth about $133,000. Horan Capital Management acquired a new position in shares of Aetna during the first quarter worth about $157,000. Finally, Guardian Life Insurance Co. of America increased its position in shares of Aetna by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 1,353 shares of the company’s stock worth $173,000 after buying an additional 9 shares during the period. Hedge funds and other institutional investors own 91.86% of the company’s stock.

Aetna (NYSE AET) opened at 155.27 on Friday. Aetna has a 52 week low of $104.59 and a 52 week high of $155.93. The stock’s 50 day moving average is $147.24 and its 200 day moving average is $132.57. The company has a market capitalization of $51.50 billion, a PE ratio of 47.35 and a beta of 0.54.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 28th. Shareholders of record on Thursday, July 13th will be paid a $0.50 dividend. The ex-dividend date of this dividend is Tuesday, July 11th. This represents a $2.00 dividend on an annualized basis and a yield of 1.29%. Aetna’s dividend payout ratio (DPR) is presently 62.31%.

Aetna Company Profile

Aetna Inc is a diversified healthcare benefits company. The Company operates through three segments: Health Care, Group Insurance and Large Case Pensions. It offers a range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans, medical management capabilities, Medicaid healthcare management services, Medicare Advantage and Medicare Supplement plans, workers’ compensation administrative services and health information technology (HIT) products and services.

Get a free copy of the Zacks research report on Aetna (AET)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aetna (NYSE:AET)

Receive News & Ratings for Aetna Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aetna Inc. and related companies with MarketBeat.com's FREE daily email newsletter.